The Critical Path for Parkinson’s Consortium Welcomes ESCAPE Bio
C-Path’s Critical Path for Parkinson’s Consortium is thrilled to welcome its newest member, ESCAPE Bio, a clinical-stage company developing novel, precisely targeted therapies for genetic neurodegenerative diseases. We applaud ESCAPE Bio for their willingness to share data, consistent with CPP’s open science strategy for advancing drug development tools for Parkinson’s disease trials.
